SRT2104

SRT2104 is an investigational small molecule developed as a selective activator of the NAD-dependent protein deacetylase sirtuin 1 (SIRT1). It was originally studied by Sirtris Pharmaceuticals and later GlaxoSmithKline. The drug has been evaluated in clinical trials for conditions such as type 2 diabetes, psoriasis, sepsis, and muscular atrophy. Mechanistically, it acts by modulating the activity of SIRT1, which plays a role in energy homeostasis and metabolic regulation including glucose metabolism, lipid metabolism, and oxidative stress response. Although early studies showed some biological effects consistent with SIRT1 activation—such as improved lipid profiles and potential mitochondrial benefits—clinical development for type 2 diabetes was discontinued after Phase II trials due to lack of efficacy on glycemic endpoints. However, it continues to be used in preclinical research exploring sirtuin biology[2][8][9].

Other names

SRT2104SRT-2104SRT 2104